TMSC treatment inhibited T-cell-mediated inflammatory responses by reducing the levels of IL-6, IL-1β, TNF-α, IL-4, and B-cell-mediated serum IgE in mice with AD. The gene discussed is IL6; the disease is Alzheimer disease.